Resistance to keratolysis boosted by crosslinking

Article

Optimal resistance to in vitro keratolysis by collagenase A can be achieved by collagen crosslinking the deepithelialized anterior corneal surface for 30 minutes, according to a recently published study.

Optimal resistance to in vitro keratolysis by collagenase A can be achieved by collagen crosslinking the deepithelialized anterior corneal surface for 30 minutes, according to a study published in Cornea.

In a basic investigation, Barron artificial anterior chambers were used to perform ex vivo crosslinking of human corneas. The deepithelialized corneas were pretreated with riboflavin solution and irradiated with ultraviolet A (UVA) light for various durations. The corneas were then trephined and incubated with 0.3% collagenase A solution at 37 °C.

It was found that deepithelialized corneas that received no UV light and no riboflavin dissolved in 5.8 ± 0.6 hours. Increased resistance to dissolution was found in the crosslinked corneas, which demonstrated a time to dissolution of 17.8 ± 2.6 hours.

Longer UVA exposure increased the corneal tissues' resistance to collagenase, reaching a plateau at 30 minutes. Crosslinking the anterior corneas only provided the same amount of resistance as crosslinking both the anterior and posterior corneas.

Corneas that had been gamma-irradiated did not benefit from further crosslinking. They dissolved in 5.6 ± 1.2 hours when further crosslinked and 6.1 ± 0.6 hours when not.

To view an abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.